As the COVID-19 pandemic slowly starts to ease globally, efforts are already gearing up to predict the next potential pandemic. One institute researching the increasing number of diseases transmitted from animals to humans is Canada’s Vaccine and Infectious Disease Organization, part of the University of Saskatchewan. Now, together with collaborators including the Canadian government, it’s sponsoring a phase II trial of COVAC-2, a squalene-in-water adjuvanted microsphere peptide-based protein subunit vaccine that contains a portion of the SARS-CoV-2 spike protein.
The commercial success of COVID-19 mRNA vaccines has other companies in the space “looking in the attic, so to speak,” to see if they have any patents they can assert against components of the vaccines so they can get a percentage of the sales, Aziz Burgy, a patent attorney, told BioWorld. Given the global spread of the pandemic and how quickly it came on, the vaccines have generated billions of dollars in sales in a short period of time, and other companies want a share, he said. He compared today’s patent infringement cases against the vaccine producers to the litigation seen in the early days of the smartphone revolution when other high-tech companies scrambled for a piece of Apple’s and Samsung’s profits.
In an effort to increase global access to COVID-19 technologies, the World Health Organization’s COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement May 12 with the U.S. NIH for research tools, early stage vaccines and diagnostics.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Accelus, Cepheid, Medmira, Remedee Labs, Wysa.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amicus, Ascletis, Cue, Eli Lilly, Immuron, Incyte, Iterum, Kiromic, Regulus, Spine, Veru.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: CSL, Enveric, Gain, Juvenescence, Neximmune, Propanc, Rakovina, Selah, Sound, Vifor, Zealand.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Arcellx, Cognition, Genentech, Glyscend, Inovio, Medicenna, Mind, Myeloid, Rhovac, Sanofi, Scilex, Spine.
With its focus on transformative high-risk, high-reward research to drive biomedical breakthroughs, the new Advanced Research Projects Agency for Health (ARPA-H) may be a good concept, but it shouldn’t come at the expense of increased investment in basic research at the NIH, according to the bipartisan leadership of U.S. House appropriators.
Newly appointed President and CEO Jackie Shea looks to have her work cut out for her, as Inovio Pharmaceuticals Inc. decided to ditch its phase II/III COVID-19 vaccination trial in favor of pursuing a booster strategy with INO-4800. That update, disclosed during Inovio’s first-quarter earnings late May 10 alongside a likely delay in filing for approval of HPV immunotherapy candidate VGX-3100, sent the stock (NASDAQ:INO) falling 27% May 11. Over the past year, shares have fallen more than 70%.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Eisai, Gilead, Kadmon, Moleculin, Neogene, Novo Nordisk, Turning Point, Zai Lab.
RSS
